Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.

Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.

Abstract: Provided is an effective and safe method for treating or preventing a cancer using aAVC. The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Abstract: This disclosure relates to a peptide inducing immunity to SARS-CoV-2. Also, the disclosure relates to a composition containing the peptide and inducing immunity to SARS-CoV-2.

Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Abstract: The present invention provides a composition for use in activating innate immunity, comprising an immunostimulant. The present invention also provides a combination use of an immunostimulant and an artificial adjuvant vector cell.

Abstract: The present invention provides a cell activating the immune system and a pharmaceutical composition containing the cell. According to the present invention, there is provided a mammalian cell having at least one protein selected from the group consisting of E6 protein and E7 protein for early genes of human papillomavirus and a fusion protein of E6 protein and E7 protein, and CD1d protein, wherein the mammalian cell is pulsed with a CD1d ligand. According to the present invention, there are also provided a fusion protein having E7 protein, E6 protein and E7 protein in this order, a nucleic acid encoding the protein and a gene expression vector therefor.

Abstract: The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.

Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Abstract: The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.

Abstract: The present invention provides use of KLRG1 as a marker specific to memory invariant NKT cells. Using an antibody that specifically recognizes KLRG1, memory invariant NKT cells can be easily detected or isolated.

Abstract: A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor ?-chain and an exogenous T cell receptor ?-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor ?-chain and a polynucleotide encoding a T cell receptor ?-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.

Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.

Abstract: The present invention provides use of KLRG1 as a marker specific to memory invariant NKT cells. Using an antibody that specifically recognizes KLRG1, memory invariant NKT cells can be easily detected or isolated.

Abstract: The present invention provides a superior method of functional analysis of NKT cells, which enables function analysis of low frequency NKT cells, is independent of the function of autologous APCs, and can avoid an influence of secondary factors and the like.

Abstract: A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.

Abstract: The present invention provides a means to be used for a new immunotherapy of cancer or infection utilizing activation of dendritic cell (DC) by innate immunity, namely, a method of preparing a cell co-expressing a target antigen and CD1d and having an ability to activate immunity against the target antigen, comprising the following steps (a) and (b): (a) a step of transfecting an mRNA encoding the target antigen into a CD1d-expressing cell to give a cell co-expressing the target antigen and CD1d; and (b) a step of treating the cell obtained in step (a) with a CD1d ligand in a culture medium.

Abstract: The present invention provides a production method of a functional differentiated cell having a post-rearrangement genotype of a particular antigen receptor gene, which includes culturing a stem cell having the genotype in a medium to give the differentiated cell derived from the stem cell. As the stem cell having the genotype, a stem cell (e.g., ES cell) established by transplantation of the nucleus of a cell having the genotype is preferable. As the differentiated cell, NKT cell is preferable.

Abstract: The invention provides a method of evaluating the antigen presentation potential of human dendritic cells by administering ?-galactosylceramide-pulsed human dendritic cells to a non-human mammal; collecting a sample containing NKT cells from the non-human mammal; and detecting the activation of NKT cells present in the sample. The invention further provides an agent for human NKT cell immunotherapy, which contains human dendritic cells that have been assessed by the aforementioned method as those possessing an antigen presentation potential for NKT cells.

Abstract: The present invention provides a novel immunity induction method, particularly, a method of simultaneously inducing activation of NKT cells and T-cell immune responses. To be more precise, the present invention provides a target antigen and CD1d co-expressing cell, and a preparation and identification method thereof; a target antigen and CD1d co-expressing cell capable of activating immunity to the target antigen, and a preparation method thereof; an immunoinducer to a target antigen or a pharmaceutical agent, which contains a target antigen and CD1d co-expressing cell capable of activating immunity to the target antigen; a target antigen and CD1d co-expressing vector; a kit containing an expression vector and/or a CD1d ligand; and the like.